Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review

Ella J. Ariza-Heredia; Lior Nesher; Roy F. Chemaly

doi:10.1016/j.canlet.2013.09.004

Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review

Ella J. Ariza-Heredia, Lior Nesher, Roy F. Chemaly

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Review article › peer-review

136 Scopus citations

Abstract

Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, tissue-invasive CMV diseases may be associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections. Because of these direct and indirect adverse effects, prevention of CMV infection, mostly through pre-emptive therapy, is one of the essential strategies that may improve outcomes of HSCT recipients. Management of CMV infection relies mainly on intravenous (IV) antiviral therapy with ganciclovir and foscarnet, with or without IV polyclonal immunoglobulins. Although viral resistance remains rare, better tolerated antiviral agents with less serious side effects are needed, and a few will be evaluated in phase III clinical trials in the near future.

Original language	English (US)
Pages (from-to)	1-8
Number of pages	8
Journal	Cancer Letters
Volume	342
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2013.09.004
State	Published - Jan 1 2014

Keywords

Cytomegalovirus
Stem cell transplantation
Viral infections

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.canlet.2013.09.004

Cite this

@article{6e8934ae157f44d188f055a7f05da526,

title = "Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review",

abstract = "Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, tissue-invasive CMV diseases may be associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections. Because of these direct and indirect adverse effects, prevention of CMV infection, mostly through pre-emptive therapy, is one of the essential strategies that may improve outcomes of HSCT recipients. Management of CMV infection relies mainly on intravenous (IV) antiviral therapy with ganciclovir and foscarnet, with or without IV polyclonal immunoglobulins. Although viral resistance remains rare, better tolerated antiviral agents with less serious side effects are needed, and a few will be evaluated in phase III clinical trials in the near future.",

keywords = "Cytomegalovirus, Stem cell transplantation, Viral infections",

author = "Ariza-Heredia, {Ella J.} and Lior Nesher and Chemaly, {Roy F.}",

note = "Funding Information: Dr. Chemaly received research grants from AiCuris, Chimerix, and ViroPharma, Inc. He has also served on the advisory board of Astellas and ViroPharma, Inc. The remaining authors declare no conflicts of interest. Funding Information: This research is supported in part by the MD Anderson Cancer Center Support Grant, CA016672. ",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.canlet.2013.09.004",

language = "English (US)",

volume = "342",

pages = "1--8",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Cytomegalovirus diseases after hematopoietic stem cell transplantation

T2 - A mini-review

AU - Ariza-Heredia, Ella J.

AU - Nesher, Lior

AU - Chemaly, Roy F.

N1 - Funding Information: Dr. Chemaly received research grants from AiCuris, Chimerix, and ViroPharma, Inc. He has also served on the advisory board of Astellas and ViroPharma, Inc. The remaining authors declare no conflicts of interest. Funding Information: This research is supported in part by the MD Anderson Cancer Center Support Grant, CA016672.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, tissue-invasive CMV diseases may be associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections. Because of these direct and indirect adverse effects, prevention of CMV infection, mostly through pre-emptive therapy, is one of the essential strategies that may improve outcomes of HSCT recipients. Management of CMV infection relies mainly on intravenous (IV) antiviral therapy with ganciclovir and foscarnet, with or without IV polyclonal immunoglobulins. Although viral resistance remains rare, better tolerated antiviral agents with less serious side effects are needed, and a few will be evaluated in phase III clinical trials in the near future.

AB - Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, tissue-invasive CMV diseases may be associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections. Because of these direct and indirect adverse effects, prevention of CMV infection, mostly through pre-emptive therapy, is one of the essential strategies that may improve outcomes of HSCT recipients. Management of CMV infection relies mainly on intravenous (IV) antiviral therapy with ganciclovir and foscarnet, with or without IV polyclonal immunoglobulins. Although viral resistance remains rare, better tolerated antiviral agents with less serious side effects are needed, and a few will be evaluated in phase III clinical trials in the near future.

KW - Cytomegalovirus

KW - Stem cell transplantation

KW - Viral infections

UR - http://www.scopus.com/inward/record.url?scp=84887606007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887606007&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.09.004

DO - 10.1016/j.canlet.2013.09.004

M3 - Review article

C2 - 24041869

AN - SCOPUS:84887606007

SN - 0304-3835

VL - 342

SP - 1

EP - 8

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this